Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin in Pediatric HoFH (HYDRA)
NCT02226198Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2014
- Primary completion
- Jul 2015
- Modality
- Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) comparing Rosuvastatin Sequence with Placebo Sequence (2 arms). Primary endpoint: Low Density Lipoprotein Cholesterol at Day 84. Started Nov 2014; status: completed.
02
Drugs
rosuvastatin
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT02226198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226198.